JAZZ Jazz Pharmaceuticals plc

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the pharmaceuticals industry, including Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers.

Target upgraded, Moderna downgraded: Wall Street's top analyst calls

AbCellera shares skyrocket 121% as positive ABCL635 data, major partnerships and a stronger financial position boost investor confidence.

Jazz Pharmaceuticals (NASDAQ:JAZZ) executives outlined the company’s oncology growth strategy, early commercial progress for recently launched therapies and business-development priorities during the Morgan Stanley Global Healthcare Conference. Chumi Khurana, senior vice president of U.S. Oncology

Jazz Pharmaceuticals (NASDAQ:JAZZ) outlined development and commercial plans for its oncology, epilepsy and sleep franchises during a discussion with Deutsche Bank analyst David Hoang, emphasizing the expansion potential of HER2-targeted therapy Ziihera and ongoing lifecycle work for EPIDIOLEX. Zii

Actio could make Jazz's growing epilepsy franchise even stronger.

On September 15, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) completed its acquisition of privately held Actio Biosciences for $820 million upfront, adding a clinical-stage epilepsy drug called ABS-1230 to its rare disease pipeline. The deal lands weeks after Jazz posted its highest quarterly revenue ever on August 3, and raised its full-year guidance, so a fresh acquisition […]

Jazz Pharmaceuticals (NasdaqGS:JAZZ) is assessing new trials of newly approved cancer drug Ziihera beyond gastroesophageal adenocarcinoma. The company is preparing development plans to study Ziihera in breast cancer, colorectal cancer, and lung cancer indications. Management is evaluating how broader Ziihera use could reshape Jazz Pharmaceuticals' long term oncology portfolio mix. The move to test Ziihera in breast, colorectal, and lung cancer only captures part of the story for Jazz. We...

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

Jazz Pharmaceuticals’s 29.7% return over the past six months has outpaced the S&P 500 by 17%, and its stock price has climbed to $240.49 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

Jazz Pharmaceuticals (JAZZ) could see long-term value from Ziihera's pursuit of additional indicatio

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.

Quoin has now received two rare paediatric disease designations for its lead asset QRX003.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) reported that Ziihera plus chemotherapy produced a statistically significant and clinically meaningful overall-survival benefit over trastuzumab plus chemotherapy in the Phase 3 HERIZON-GEA-01 trial. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) said the overall-survival hazard ratio improved from the first interim analysis, when the result favored Ziihera but was not statistically significant. The global, […]

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Check out the companies making headlines yesterday:

AXSM begins dosing in the phase III SUMMIT study investigating AXS-05 for treating smoking cessation in adults.

Jazz up as updated HERIZON-GEA-01 results show statistically significant OS benefits for Ziihera-based regimens in first-line HER2+ gastroesophageal adenocarcinoma.

Shares of biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) jumped 2.5% in the afternoon session after the company announced positive Phase 3 HERIZON-GEA-01 trial results showing that Ziihera combined with chemotherapy achieved a statistically significant overall survival benefit in advanced gastroesophageal adenocarcinoma.

Jazz Pharmaceuticals' (JAZZ) shares are up about 45% year to date, but may still have the potential

Jazz Pharmaceuticals recently secured FDA approval for Ziihera (zanidatamab-hrii)–based regimens in first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma, supported by Phase 3 HERIZON-GEA-01 data showing longer progression-free and overall survival versus trastuzumab plus chemotherapy. This decision materially expands Ziihera’s addressable population beyond previously treated biliary tract cancer and positions Jazz more...

On Tuesday, the U.S. Food and Drug Administration (FDA) approved Jazz Pharmaceuticals plc’s two Ziihera-containing combination regimens as first-line treatments for adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma. Zanidatamab is being developed in multiple clinical trials as...

Jazz Pharmaceuticals' Ziihera wins FDA approval for first-line HER2-positive GEA, expanding its market and showing strong progression-free and survival benefits.

The stock market rose Tuesday amid lower oil prices and yields, but cautiously heading into Fed inflation data and Nvidia earnings.

Jazz Pharmaceuticals (NASDAQ:JAZZ) outlined its plans for the U.S. launch of Ziihera following FDA approval of the therapy for first-line HER2-positive unresectable, locally advanced or metastatic gastroesophageal adenocarcinoma, or GEA. Ziihera, or zanidatamab, is approved in combination with tisl

Jazz stock bounced off its buy zone Tuesday after the FDA approved its drug, Ziihera, to treat a form of stomach cancer.

Healthcare stocks rose late Tuesday afternoon with the NYSE Healthcare Index and the State Street He

Ziihera can now be used as an initial treatment for all HER2-positive gastroesophageal adenocarcinomas, dramatically expanding the drug’s market potential.

The FDA approved Jazz Pharma’s Ziihera with chemotherapy, with or without BeOne’s Tevimbra, as an initial treatment for advanced HER2-positive gastroesophageal cancer.

Jazz Pharmaceuticals (NASDAQ:JAZZ) has secured FDA approval for two Ziihera-containing regimens in first-line HER2-positive advanced gastroesophageal adenocarcinoma, expanding the drug into an earlier treatment setting after Phase 3 data showed improvements in progression-free and overall survival. Key Investor TakeawaysThe FDA approved Ziihera plus tislelizumab and chemotherapy for first-line treatment of HER2+ advanced GEA patients with IHC 3+ or IHC 2+/ISH+ disease, regardless of PD-L1 status

Jazz Pharmaceuticals (JAZZ) has drawn investor attention after recent share price moves, with the stock closing at $254.28 as of 18 August 2026. This came after modest gains over the past week and year. See our latest analysis for Jazz Pharmaceuticals. For context, the recent 2.24% 1 day share price return builds on a much stronger pattern, with year to date share price gains of 46.86% and a 1 year total shareholder return of 104.09%, signalling firm positive momentum. If Jazz Pharmaceuticals...

Zymeworks (NASDAQ:ZYME) shares climbed nearly 4. 0% in pre-market trading as investors positioned themselves ahead of an important U.

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.

Jazz Pharmaceuticals (JAZZ) just made a bet on a disease that many investors have never heard of. On August 10, the drugmaker agreed to buy privately held Actio Biosciences. The prize is an experimental medicine aimed at a childhood epilepsy so rare, and so severe, that no FDA-approved ...

Jazz Pharmaceuticals delivered a positive Q2, with a strong 16% year-over-year revenue increase driven primarily by its oncology and rare disease portfolios. Management attributed the quarter’s performance to robust demand for flagship products like Xywav and Epidiolex, as well as accelerating uptake of new oncology therapies. CEO Renée Galá noted, “Our results reflect an intense focus on aligned execution across our diversified portfolio, sustained demand of our commercial products and progress

AXSM's Q2 earnings meet estimates, but revenues miss forecasts. Auvelity and other product sales drive year-over-year revenues.

Jazz Pharmaceuticals' (JAZZ) recent acquisition of Actio Biosciences' KCNT1 epilepsy asset "makes se

As part of the deal, Actio Biosciences will spin out a new company focused on genetic rare neurological diseases.

Revenue hit $1.2 billion with oncology sales surging and Xywav demand accelerating.

Explore Jazz's (JAZZ) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Actio Biosciences, which will receive $820 million up front in the deal, adds to a major upswing in private biotech buyouts seen throughout this year.

JAZZ vs. TECH: Which Stock Is the Better Value Option?